Detalles de la búsqueda
1.
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Diabetes Obes Metab
; 26(3): 961-970, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38073422
2.
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).
Endocr J
; 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38658349
3.
Improvement of ß-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
J Clin Endocrinol Metab
; 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38695547
4.
Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
BMJ Open
; 12(5): e056885, 2022 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35584872
5.
Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria.
J Clin Transl Endocrinol
; 22: 100244, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33318949
Resultados
1 -
5
de 5
1
Próxima >
>>